Deliver Your News to the World

Agilent Technologies introduces industry’s first dual-mode gene expression microarray platform


Scientists can now perform commercial-quality, one- or two-color gene expression studies on same platform

PALO ALTO, Calif., Jan. 9, 2006, Agilent Technologies Inc. (NYSE: A) today launched the industry’s first dual-mode, one-color/two-color microarray platform, offering researchers unprecedented flexibility and performance for gene expression research. Gene expression profiling represents a majority of all DNA microarray experiments.

“Until now, researchers selecting a gene expression microarray platform had to choose between convenience and resolving power,” said Michael Booth, Agilent business manager, genomics. “Scientists no longer have to make that choice.”

“In a direct comparison of two RNA samples, two-color microarrays usually give the most accurate results, particularly for small changes of expression levels, because two RNAs are co-hybridized to the arrays,” said Calvin Lin, Ph.D., director of gene expression, Regeneron Pharmaceuticals, who recently completed comprehensive testing of the dual-mode microarrays.

“However, for experiments involving large numbers of samples or across long time spans, experimental design for one-color microarrays is more straightforward and cost-efficient,” Lin continued. “The data we have generated demonstrates Agilent’s commitment to providing both excellent platform performance and superb quality control.”

Agilent’s dual-mode microarrays can be used for either one-color or two-color experiments to match researchers’ requirements. “By combining the flexibility of our dual-mode gene expression platform and the ability of customers to design their own microarrays through our eArray website, Agilent now offers the most versatile gene expression microarray platform available,” Booth said. “It is unique in its ability to adapt to scientists’ research requirements and goals, even as they evolve day by day.”

Also unrivaled is the sensitivity (limit of detection) of the dual-mode microarrays. The products take advantage of superior-quality 60-mer probes, made possible by Agilent’s proprietary inkjet (in situ) microarray manufacturing process. Like all Agilent microarrays, the dual-mode products are part of Agilent’s total microarray solution. Thus, scientists can take advantage of the flexibility and performance of the dual-mode microarrays without the need to invest in additional capital equipment.

Platform Selected for FDA Project

The U.S. Food and Drug Administration recently selected Agilent’s dual-mode platform as part of its Microarray Quality Control (MAQC) project, designed to provide quality control guidance to the microarray industry.

“Our vision is to be able to assess the proficiency of a laboratory in running good microarray experiments,” said Dr. Leming Shi, computational chemist, National Center for Toxicological Research, FDA, and architect of the MAQC project. “We’re glad to see Agilent in the project, and we see positive responses to the one-color data from Agilent. Experimental design is unified, compared with other platforms, so there’s a lot of value in having two sample mixtures to evaluate the platform.”

Icoria Inc., a leading biotechnology company focused on the discovery, development and commercialization of diagnostics and targeted therapeutics, submitted data from the new Agilent platform for the MAQC project.

“This is the first one-color data I’ve ever generated, and I’m excited about using it to make research decisions,” said FDA scientist Tucker Patterson, Ph.D. “The workflow is very similar to the two-color work we’ve been doing, so there’s been no disruption caused by the new platform.”

About Agilent in Genomics

Agilent is a leading provider of complete microarray-based research solutions with customers worldwide. With its proprietary ink-jet based manufacturing technique, Agilent provides highly sensitive 60-mer oligo microarrays in custom and catalog formats. Agilent recently acquired Computational Biology Corp., founded by professors Richard Young and David Gifford of MIT and the Whitehead Institute. The acquisition provides access to expertise in location analysis and patents in this area. Researchers can now access the Encode, Yeast, Human and Mouse promoter arrays.

Agilent also offers a 48-slide high-throughput microarray scanner, the Agilent 2100 Bioanalyzer with LabChip kits for sample quality analysis, feature extraction software, Silicon Genetics software products, Rosetta gene expression data analysis systems and a range of reagents. Product information is available online at
About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is the world’s premier measurement company and a technology leader in communications, electronics, life sciences and chemical analysis. The company’s 21,000 employees serve customers in more than 110 countries. Agilent had net revenue of $5.1 billion in fiscal 2005. Information about Agilent is available on the Web at


This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.